


CONQUERING PARKINSON'S DISEASE



CONFIDENTIAL — NOT FOR DISTRIBUTION



WHO IS JONATHAN SACKNER-BERNSTEIN, MD, FOUNDER AND CEO?

Inventor of RB-190 for Parkinson's

Former Senior FDA Official with 2 Commissioner's awards

Former DARPA insider supporting programs in neurotech and big data

Renowned academic cardiologist and clinical trialist

Expert in clinical development and regulatory affairs

Success as *Disruptor*

- **Coreg**: beta-blockers were contraindicated for heart failure before he helped launch Phase 2 trials; beta-blockers became standard of care
- **Biventricular pacing**: repurposed cardiac pacemakers were shunned before initial clinical trials which he helped design; now a \$5B market
- **Natrecor**: J&J purchased for \$2.4B to be a blockbuster prior to his publications that led to its abandonment and withdrawal

EMBRACING THE OPPORTUNITY

Parkinson's dogmas are based on flawed understanding of the disease.

Dopaminergic neurons determine health vs. disease and experience Parkinson's as a disease of dopamine excess – and thereby toxicity.

Reducing dopamine with RB-190 reverses pathology in 9 models of the disease – ***validating the therapeutic approach.***

Manufacturing of clinical-grade, GMP, reformulated drug is complete.


The next step in development of RB-190 – a patented, repurposed drug – is a Phase 2A trial treating people with Parkinson's.

We are seeking \$6.25M in the current Seed round using SAFE instrument.


THE MARKET

- There are no therapies on the market or in clinical trials that reduce dopamine.
- RB-190 will be first and only therapy for PD based on this data-driven, science-based approach to the disease.

High Prevalence (US)



Onerous Costs (US)



TISSUE DOPAMINE LEVELS ARE LOW IN PD. THERE'S A BUT.

Reports of dopamine deficiency from the 1960s were based on tissue levels – **but the importance of intracellular levels of dopamine was not known until the 1980s.**

Tabelle 2. Dopamin in Nucleus caudatus und Putamen von normalen und von parkinsonkranken Menschen

Gehirnregion	Dopamin (ug/g Yeuchigewebe)	
	Normal	Parkinson
Nucleus Caudatus	2,46 (1,51-2,81) n=6	0,36 (0-1,65) n=7
Putamen	3,43 (1,24-5.87) n=6	0.19 (0-0,97) n=7

The 1960s studies did **not** demonstrate:


- ❌ Cause of Parkinson's
- ❌ Severity of Parkinson's
- ❌ Risk of worsening
- ❌ Optimal treatment of Parkinson's

●
1960s

BROADENED UNDERSTANDING OF DOPAMINE'S ROLE IN PD

Starting in the 1980s, the scientific literature **taught**:

- ✓ Dopamine levels inside cells, and specifically in the cytosol, are what determine function or dysfunction.
- ✓ Normal function requires enough dopamine inside the cells; tissue levels do not determine function.
- ✓ Excess dopamine inside the cells causes neuron dysfunction and death; tissue levels do not determine toxicity.




1980s

1990s


2000s

NEURONS EXPERIENCE PD AS DOPAMINE EXCESS & TOXICITY


↑ TH ACTIVITY
rate-limiting enzyme
in dopamine synthesis



↑ DOPAMINE TURNOVER
HVA / DA
(% control)




↑ CYTOSOLIC DOPAMINE CONTENT
PD / Control



● Control ● Parkinson's

Disease Severity
 ● Mild
 ● Moderate
 ● Severe



1980s

1988

1990


2000s

2021


REDUCING DOPAMINE REVERSES PD PATHOLOGY

RB-190 EFFECTIVE IN 9 PRECLINICAL MODELS OF PD

(fold change)



2025



THE RIGHT BRAIN BIO TEAM



JONATHAN SACKNER-BERNSTEIN, MD

CEO & Founder; Clinical, Regulatory

Inventor of RB-190, ex-FDA Senior Official and ex-DARPA contractor with track record of successful adoption of contrarian views/products.



KEITH A. ORRIS

Lead, Strategy and Business Development

Strategic corporate advisor focused on disruptive products (health care, tech and others). Ex-innovation officer for university incubator and venture fund.



TAMIM BRAISH, PhD

Lead, Chemistry and Manufacturing

Expert chemist: process & analytic chemistry, formulation, regulatory and quality. Led early synthesis group (CMC to Phase 2) at Pfizer (neurosciences).



TIMOTHY J. LABUA, JD

Corporate Counsel, Crowell Life Sciences

Life sciences counselor with expertise in financing, strategic partnerships and M&A transactions.



ANNE HEROLD LI, MPH, JD

Intellectual Property, Brownstein, Hyatt

Expert in litigation, counseling and patent procurement. Recognized as "Rising Star" in IP by Super Lawyers Magazine.



ANGELA DRISCOLL, CPA, MSA

Fractional controller, Browne Consulting

Lead of biotech focused Browne Consulting team providing operational accounting and finance support.

SCIENTIFIC ADVISORY BOARD



ROGER BARKER

MBBS, MRCP, PhD

Professor of Clinical Neuroscience at University of Cambridge. Director, UK Regenerative Medicine Platform.



JIM SURMEIER

PhD

Chair, Department of Neuroscience, Professor at Northwestern U., AAAS Fellow, MJFF Scientific Advisor.



JASON CONNOR

PhD

Visiting professor Johns Hopkins Bloomberg School of Public Health, ex-FDA Advisor, expert in innovative & adaptive clinical trial design.



PAUL BLAKE (1948-2024)

MBBS, FRCP


Experienced pharma executive with leadership of development programs including programs in Parkinson's.

RIGHT BRAIN BIO: FUND RAISING AND ANTICIPATED MILESTONES


*To date:
Bootstrapped*



*Seed:
\$6.25M via
SAFE*



*Series A:
\$30M as priced equity*



LAUNCHING PHASE 2A CLINICAL TRIAL

To mitigate FDA risks, Phase 2A trial to be conducted in Australia (using FDA input)

Established Australian subsidiary to leverage R&D incentives

Engaged Parkinson's disease clinical trial network in Australia

Evaluating CRO options in Australia

Timeline:

- Submit to HREC in 2Q26 (for permission to launch trial)
- Launch trial 3Q26
- Initial data read-out 1Q27

USES OF SEED FUNDS

<u>Category</u>	<u>2026*</u>	<u>2027</u>	<u>Total</u>
SG&A			\$ 938,000
Consultants	\$ 125,000	\$ 125,000	
Insurance	\$ 50,000	\$ 50,000	
Legal	\$ 125,000	\$ 75,000	
Administration	\$ 90,400	\$ 106,800	
Payroll	\$ 95,400	\$ 95,400	
R&D			\$ 5,312,000
Consulting	\$ 212,850	\$ 155,900	
Phase 2 Trial	\$ 1,041,330	\$ 2,201,120	
Drug Supply	\$ 500,000	\$ -	
Payroll	\$ 260,400	\$ 640,400	
Travel & Monitoring	\$ 75,000	\$ 75,000	
Total			\$ 6,250,000

* Costs prior to 2026 folded into 2026

Seed round of \$6.25M delivers clinical proof-of-concept data

THE RIGHT BRAIN APPROACH

Rather than:

- Developing a new drug that requires tens of millions of dollars to get to Phase 2, RBB uses an existing drug that can reach Phase 2 at cost ~\$1M.
- Building a company with deep, costly team, RBB leverages its network of experts to establish a lean management structure and control burn.
- Accepting development strategies from prior PD drugs, RBB integrates lessons as FDA insider.
- Falling victim to FDA's limitations, we're moving operations to Australia to advance the program more quickly without sacrificing quality.

RIGHT BRAIN BIO: NEXT STEPS


- 2025 Secured \$1.25M to manufacture RB-190
- 2Q26 Complete Seed fund raise (\$6.25M)
- 2Q26 Submit: Australia HREC / IND
- 3Q26 Launch Phase 2A clinical trial
- 1Q27 Report clinical proof of concept data

CONTACT

Jonathan Sackner-Bernstein, MD

jsb@rightbrainbio.com

+1.212.888.2589




DISCLOSURES

THIS DOCUMENT IS FOR INFORMATION PURPOSES ONLY AND IS BEING PROVIDED TO YOU SOLELY AS A POTENTIAL INVESTOR WHO MAY CONSIDER AN INVESTMENT IN RIGHT BRAIN BIO, INC. ("THE COMPANY"). ANY REPRODUCTION OR DISTRIBUTION OF THIS DOCUMENT, IN WHOLE OR IN PART, OR THE DISCLOSURE OF ITS CONTENTS WITHOUT PRIOR WRITTEN CONSENT OF THE COMPANY IS PROHIBITED. THE INFORMATION CONTAINED IN THIS CONFIDENTIAL DOCUMENT IS CONFIDENTIAL. IT IS BEING PRESENTED TO YOU WITH THE UNDERSTANDING THAT, WITHOUT THE EXPRESS WRITTEN CONSENT OF THE COMPANY, YOU WILL NOT: (I) DISCLOSE OR DISCUSS THE INFORMATION CONTAINED IN THIS DOCUMENT, OR (II) REPRODUCE OR USE THE INFORMATION CONTAINED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN TO EVALUATE AN INVESTMENT IN THE COMPANY.

NO REPRESENTATIONS OR WARRANTIES

THIS DOCUMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONTAIN ALL OF THE INFORMATION REQUIRED TO EVALUATE A POSSIBLE INVESTMENT IN THE COMPANY'S SECURITIES. YOU AGREE AND ACKNOWLEDGE THAT THIS DOCUMENT IS NOT A SOLICITATION FOR INVESTMENT IN THE COMPANY'S SECURITIES, IS NOT INTENDED TO FORM THE BASIS OF ANY INVESTMENT DECISION BY YOU, AND DOES NOT CONSTITUTE INVESTMENT, TAX, OR LEGAL ADVICE. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, IS OR WILL BE GIVEN BY THE COMPANY OR ANY OF ITS AFFILIATES, DIRECTORS, OFFICERS, EMPLOYEES, ADVISORS, OR OTHER PERSONS REGARDING THE ACCURACY OR COMPREHENSIVENESS OF THE INFORMATION IN THIS DOCUMENT. NO RESPONSIBILITY OR LIABILITY IS ACCEPTED REGARDING THE ACCURACY OR SUFFICIENCY OF THE INFORMATION OUTLINED IN THIS DOCUMENT OR FOR ANY ERRORS OR MISSTATEMENTS, NEGLIGENT OR OTHERWISE, RELATING THERETO. YOU AGREE AND ACKNOWLEDGE THAT THE INFORMATION IN THIS DOCUMENT IS PRELIMINARY AND SUBJECT TO CHANGE, AND ANY SUCH CHANGES MAY BE MATERIAL. THE COMPANY DISCLAIMS ANY DUTY TO UPDATE THE INFORMATION CONTAINED IN THIS DOCUMENT.



DISCLOSURES

FORWARD-LOOKING STATEMENTS

CERTAIN INFORMATION INCLUDED IN THIS DOCUMENT MAY CONSTITUTE FORWARD-LOOKING STATEMENTS, AS DEFINED IN THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995, AS AMENDED, WHICH ARE SUBJECT TO RISKS AND UNCERTAINTIES. FORWARD-LOOKING STATEMENTS ARE STATEMENTS OTHER THAN HISTORICAL INFORMATION OR STATEMENTS OF CURRENT CONDITION. THEY MAY BE IDENTIFIED USING TERMS SUCH AS “BELIEVES,” “ANTICIPATES,” “EXPECTS,” “INTENDS,” “MAY,” “WILL,” “ESTIMATE,” AND OTHER VARIATIONS OF COMPARABLE TERMINOLOGY. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE SUGGESTED BY THESE FORWARD-LOOKING STATEMENTS. MANY OF THESE RISKS AND UNCERTAINTIES ARE BEYOND THE COMPANY’S CONTROL; ACCORDINGLY, THERE CAN BE NO ASSURANCE THAT THE FORWARD-LOOKING STATEMENTS IN THIS DOCUMENT WILL OCCUR. THERE CAN BE NO ASSURANCE THAT THE COMPANY CAN SUCCESSFULLY ACHIEVE ANY PROJECTED FUTURE PERFORMANCE. BECAUSE THIS DOCUMENT IS BASED UPON ESTIMATES AND ASSUMPTIONS ABOUT CIRCUMSTANCES AND EVENTS THAT HAVE NOT TAKEN PLACE AND ARE SUBJECT TO MATERIAL VARIATION, THERE CAN BE NO ASSURANCE THAT THE MATTERS, STRATEGIES, AND GOALS COVERED HEREIN WILL BE ATTAINED OR, IF ACHIEVED, WILL PRODUCE THE CONTEMPLATED RETURNS OR OTHERWISE BE PROFITABLE. IN CONSIDERING ANY PERFORMANCE DATA IN THIS DOCUMENT, REMEMBER THAT PAST OR TARGETED PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS, AND THERE CAN BE NO ASSURANCE THAT THE COMPANY WILL ACHIEVE COMPARABLE RESULTS OR THAT TARGET RETURNS WILL BE MET. LIKEWISE, THERE CAN BE NO ASSURANCE THAT THE ESTIMATES, ASSUMPTIONS, EXPECTATIONS, PLANS, OR STRATEGIES DESCRIBED IN THIS DOCUMENT WILL NOT CHANGE FROM THOSE PRESENTED HEREIN. THE COMPANY UNDERTAKES NO RESPONSIBILITY TO UPDATE ANY INFORMATION IN THIS DOCUMENT, WHETHER TO REFLECT EVENTS OR CHANGES IN TERMS OR OTHERWISE, AFTER THE DELIVERY DATE OF THIS DOCUMENT.

